ArticleCureus2026
Miller Fisher Syndrome in Morocco: A 14-Year Retrospective Study of 27 Cases at a Tertiary Neurology Center.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionMiller Fisher syndrome (MFS) is a rare, acute immune-mediated neuropathy characterized by the classic triad of ophthalmoplegia, ataxia, and areflexia. Epidemiological and clinical data from North Africa remain scarce. The primary objective of this study was to provide a comprehensive description of the epidemiological, clinical, neurophysiological, and outcome characteristics of MFS in a Moroccan population. The secondary objective was to analyze these findings in comparison with existing literature.
methodsWe conducted a retrospective descriptive study in the Neurology Department of Mohammed VI University Hospital in Marrakech, Morocco, over a 14-year period (January 2010-December 2024). Patients were included based on the presence of the classical clinical triad or compatible clinical features supported by cerebrospinal fluid (CSF) findings and anti-GQ1b antibody testing.
resultsA total of 27 patients were included (mean age 40.2 ± 16.1 years, range 7-70). A female predominance was observed (n=17, 63%; male-to-female ratio: 0.59), and a seasonal peak occurred during winter in 14 patients (50%). Antecedent infections were reported in 15 patients (55.6%), most commonly respiratory infections (33%). The complete clinical triad was present in eight patients (29.6%). Areflexia was most frequent (77.7%), followed by ataxia (70.3%) and ophthalmoplegia (66.7%). Motor weakness and sensory disturbances were observed in 51.9% and 55.6% of patients, respectively. Albuminocytologic dissociation was found in 59.3% of cases, and anti-GQ1b antibodies were positive in 69.2% of patients, as all patients underwent antibody testing. Regarding treatment, 59.3% received intravenous immunoglobulins and 25.9% underwent plasmapheresis; outcomes were favorable, with complete recovery in all patients at six months.
conclusionThis study represents one of the largest reported series of MFS from North Africa and provides a detailed descriptive characterization of the disease in a Moroccan cohort. While trends such as female predominance and winter peak were observed, these should be interpreted with caution due to the small sample size and retrospective design. Similarly, although most patients received immunotherapy and achieved full recovery, causal inferences regarding treatment efficacy cannot be drawn. Despite frequent overlap with Guillain-Barré syndrome manifestations, the overall prognosis in this cohort was excellent.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.